ArticleF1000Research2016
Open drug discovery for the Zika virus.
Article in F1000Research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- School of cheminformatics in Latin America.Journal of cheminformatics · 2023Article
- Discovery of New Zika Protease and Polymerase Inhibitors through the Open Science Collaboration Project OpenZika.Journal of chemical information and modeling · 2022Article
- Using logical constraints to validate statistical information about disease outbreaks in collaborative knowledge graphs: the case of COVID-19 epidemiology in Wikidata.PeerJ. Computer science · 2022Article
- A review on Zika virus outbreak, epidemiology, transmission and infection dynamics.Journal of biological research (Thessalonike, Greece) · 2020Review
- Applications of machine learning and artificial intelligence for Covid-19 (SARS-CoV-2) pandemic: A review.Chaos, solitons, and fractals · 2020Review
- Déjà vu: Stimulating open drug discovery for SARS-CoV-2.Drug discovery today · 2020Review
- Article
- Review
- Computer-Assisted and Data Driven Approaches for Surveillance, Drug Discovery, and Vaccine Design for the Zika Virus.Pharmaceuticals (Basel, Switzerland) · 2019Review
- Development of Small-Molecule Inhibitors Against Zika Virus Infection.Frontiers in microbiology · 2019Review
- Hydroxychloroquine Inhibits Zika Virus NS2B-NS3 Protease.ACS omega · 2018Article
- High Throughput and Computational Repurposing for Neglected Diseases.Pharmaceutical research · 2018Review
- The A-Z of Zika drug discovery.Drug discovery today · 2018Review
- Polymeric Prodrugs Targeting Polyamine Metabolism Inhibit Zika Virus Replication.Molecular pharmaceutics · 2018Article
- In Silico Designed Axl Receptor Blocking Drug Candidates Against Zika Virus Infection.ACS omega · 2018Article
- Zika puzzle in Brazil: peculiar conditions of viral introduction and dissemination - A Review.Memorias do Instituto Oswaldo Cruz · 2017Review
- Screening Bioactives Reveals Nanchangmycin as a Broad Spectrum Antiviral Active against Zika Virus.Cell reports · 2017Article
- Recent Perspectives on Genome, Transmission, Clinical Manifestation, Diagnosis, Therapeutic Strategies, Vaccine Developments, and Challenges of Zika Virus Research.Frontiers in microbiology · 2017Review
- Zika Virus: An Emerging Global Health Threat.Frontiers in cellular and infection microbiology · 2017Review
- OpenZika: An IBM World Community Grid Project to Accelerate Zika Virus Drug Discovery.PLoS neglected tropical diseases · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Zika virus (ZIKV) outbreak in the Americas has caused global concern that we may be on the brink of a healthcare crisis. The lack of research on ZIKV in the over 60 years that we have known about it has left us with little in the way of starting points for drug discovery. Our response can build on previous efforts with virus outbreaks and lean heavily on work done on other flaviviruses such as dengue virus. We provide some suggestions of what might be possible and propose an open drug discovery effort that mobilizes global science efforts and provides leadership, which thus far has been lacking. We also provide a listing of potential resources and molecules that could be prioritized for testing as in vitro assays for ZIKV are developed. We propose also that in order to incentivize drug discovery, a neglected disease priority review voucher should be available to those who successfully develop an FDA approved treatment. Learning from the response to the ZIKV, the approaches to drug discovery used and the success and failures will be critical for future infectious disease outbreaks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.